Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...

doxorubicin or pirarubicin), whether immediately after surgery or after 2 weeks' delay, had similar outcomes to those who did not. By contrast, the 35 patients who received intravesical BCG ...

Discover how a TB vaccine could revolutionise bladder cancer treatment. Find out more about this groundbreaking study.

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

Investigators trained and validated a deep-learning AI model to identify patients with high-risk NMIBC unlikely to benefit from BCG. Artificial ... in The Journal of Urology.

ImmunityBio (IBRX) announced U.S. Urology Partners ... Calmette-Guerin rBCG to address the current shortage of TICE BCG in the U.S. “The shortage of BCG has real consequences, especially ...

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly ...

The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S. shortages and provide an alternative source of BCG, a critical standard-of-care in bladder cancer Multiple urology centers ...

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

“Constrained BCG supply has improved stewardship of a limited resource but has come at a high cost to our patients,” said Dr. Chad Reichard, Co-Director of Clinical Research, Urology of Indiana.